Framework for the Provision of Parenteral Systemic Anti-Cancer Therapies and Other Biologicals Including Immunotherapies

The East Midlands Pharmacy Collaborative has completed the award stage of a procurement process titled "Framework for the Provision of Parenteral Systemic Anti-Cancer Therapies and Other Biologicals Including Immunotherapies". This contract pertains to the health services industry and is aimed at providing essential therapies to participating purchasing authorities across the United Kingdom. The open procedure used for this procurement process was conducted above-threshold, with the tender period having concluded on 11th October 2024.

The awarded contract, valued at £2,760,000, commenced on 1st May 2025 and is set to end on 30th April 2027. The buyer's administration is located at the Florence Nightingale Community Hospital in Derby, with Jane Brailsford as the contact point. This framework creates significant opportunities for specialised healthcare service providers, especially those experienced in managing anti-cancer therapies and working within the NHS framework.

Businesses well-suited to compete in similar future tenders include large-scale suppliers with robust distribution networks capable of delivering tailored medical services across multiple locations in the United Kingdom. In particular, companies equipped to partner with SMEs could benefit from such procurement opportunities, as this tender underscores the East Midlands Pharmacy Collaborative's support for fostering SME involvement.